HRP20230201T1 - Oksadiazol aminski spojevi derivati kao inhibitor histonske deacetilaze 6 i farmaceutska kompozicija koja sadrži iste - Google Patents
Oksadiazol aminski spojevi derivati kao inhibitor histonske deacetilaze 6 i farmaceutska kompozicija koja sadrži iste Download PDFInfo
- Publication number
- HRP20230201T1 HRP20230201T1 HRP20230201TT HRP20230201T HRP20230201T1 HR P20230201 T1 HRP20230201 T1 HR P20230201T1 HR P20230201T T HRP20230201T T HR P20230201TT HR P20230201 T HRP20230201 T HR P20230201T HR P20230201 T1 HRP20230201 T1 HR P20230201T1
- Authority
- HR
- Croatia
- Prior art keywords
- amine
- oxadiazol
- pyrimidin
- difluoromethyl
- cyclobutyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 12
- -1 Oxadiazole amine Chemical class 0.000 title claims 8
- 239000008194 pharmaceutical composition Substances 0.000 title claims 3
- 229940122617 Histone deacetylase 6 inhibitor Drugs 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 201000010099 disease Diseases 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 9
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 6
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 6
- 102000003964 Histone deacetylase Human genes 0.000 claims 4
- 108090000353 Histone deacetylase Proteins 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 claims 3
- IWLBNXJONYNAEW-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-(1-phenylcyclobutyl)pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C1=CC=CC=C1)F IWLBNXJONYNAEW-UHFFFAOYSA-N 0.000 claims 3
- JPVLSBUZEKWGHX-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-(1-pyridin-2-ylcyclobutyl)pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C1=NC=CC=C1)F JPVLSBUZEKWGHX-UHFFFAOYSA-N 0.000 claims 3
- XYEUQTIOPNGIBI-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(2-fluorophenyl)cyclobutyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C1=C(C=CC=C1)F)F XYEUQTIOPNGIBI-UHFFFAOYSA-N 0.000 claims 3
- KQAYHVMWQWFKFV-UHFFFAOYSA-N N-[1-(2-chlorophenyl)cyclobutyl]-5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound ClC1=C(C=CC=C1)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)F KQAYHVMWQWFKFV-UHFFFAOYSA-N 0.000 claims 3
- DLAYBQQQQIQTMD-UHFFFAOYSA-N N-[1-(3-chlorophenyl)cyclobutyl]-5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound ClC=1C=C(C=CC=1)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)F DLAYBQQQQIQTMD-UHFFFAOYSA-N 0.000 claims 3
- 125000002947 alkylene group Chemical group 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 3
- LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 claims 3
- 229930192474 thiophene Natural products 0.000 claims 3
- NZUUXQSBKZPFKK-UHFFFAOYSA-N 4-piperazin-1-ylmorpholine Chemical compound C1CNCCN1N1CCOCC1 NZUUXQSBKZPFKK-UHFFFAOYSA-N 0.000 claims 2
- OHUXVGIHPZKNEF-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-(1-phenylcyclopentyl)pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCCC1)C1=CC=CC=C1)F OHUXVGIHPZKNEF-UHFFFAOYSA-N 0.000 claims 2
- IRFXHUXQYBARTM-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-(1-phenylcyclopropyl)pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CC1)C1=CC=CC=C1)F IRFXHUXQYBARTM-UHFFFAOYSA-N 0.000 claims 2
- URIYDONQDHNSLI-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(3,4-difluorophenyl)cyclopropyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CC1)C1=CC(=C(C=C1)F)F)F URIYDONQDHNSLI-UHFFFAOYSA-N 0.000 claims 2
- HNEATXXHHGDQQF-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(3-fluorophenyl)cyclobutyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C1=CC(=CC=C1)F)F HNEATXXHHGDQQF-UHFFFAOYSA-N 0.000 claims 2
- NYWYVJDCLKGRIO-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(3-methoxyphenyl)cyclobutyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C1=CC(=CC=C1)OC)F NYWYVJDCLKGRIO-UHFFFAOYSA-N 0.000 claims 2
- XWIRZMLXWLSWLU-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(4-fluorophenyl)cyclobutyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C1=CC=C(C=C1)F)F XWIRZMLXWLSWLU-UHFFFAOYSA-N 0.000 claims 2
- IBSOZXONCGPOID-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(4-methoxyphenyl)cyclobutyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C1=CC=C(C=C1)OC)F IBSOZXONCGPOID-UHFFFAOYSA-N 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 206010008805 Chromosomal abnormalities Diseases 0.000 claims 2
- 208000031404 Chromosome Aberrations Diseases 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 2
- 206010010356 Congenital anomaly Diseases 0.000 claims 2
- ZCVCIOKWHGPURY-UHFFFAOYSA-N N-[1-(4-chlorophenyl)cyclobutyl]-5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound ClC1=CC=C(C=C1)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)F ZCVCIOKWHGPURY-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 208000025966 Neurological disease Diseases 0.000 claims 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 230000003542 behavioural effect Effects 0.000 claims 2
- 210000002808 connective tissue Anatomy 0.000 claims 2
- 208000010643 digestive system disease Diseases 0.000 claims 2
- 208000016097 disease of metabolism Diseases 0.000 claims 2
- 230000002124 endocrine Effects 0.000 claims 2
- 208000030172 endocrine system disease Diseases 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 230000036244 malformation Effects 0.000 claims 2
- 230000003340 mental effect Effects 0.000 claims 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 2
- 210000002346 musculoskeletal system Anatomy 0.000 claims 2
- 206010033675 panniculitis Diseases 0.000 claims 2
- 208000023504 respiratory system disease Diseases 0.000 claims 2
- 210000004304 subcutaneous tissue Anatomy 0.000 claims 2
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 1
- OMTYOKNFBKZRCX-UHFFFAOYSA-N 3-[1-[[5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-yl]amino]cyclobutyl]phenol Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C=1C=C(C=CC=1)O)F OMTYOKNFBKZRCX-UHFFFAOYSA-N 0.000 claims 1
- GVSBHWJWYJPQIM-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-(1-phenylcyclohexyl)pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCCCC1)C1=CC=CC=C1)F GVSBHWJWYJPQIM-UHFFFAOYSA-N 0.000 claims 1
- OSAQOVAKOFTYCZ-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-(1-pyridin-3-ylcyclobutyl)pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C=1C=NC=CC=1)F OSAQOVAKOFTYCZ-UHFFFAOYSA-N 0.000 claims 1
- NPTDMWYUZVJUMM-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-(1-thiophen-2-ylcyclopropyl)pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CC1)C=1SC=CC=1)F NPTDMWYUZVJUMM-UHFFFAOYSA-N 0.000 claims 1
- CAJKPVLLDPXNAN-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-(1-thiophen-3-ylcyclobutyl)pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C1=CSC=C1)F CAJKPVLLDPXNAN-UHFFFAOYSA-N 0.000 claims 1
- ROSKJEUVGPTDCG-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-(4-phenylpiperidin-4-yl)pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCNCC1)C1=CC=CC=C1)F ROSKJEUVGPTDCG-UHFFFAOYSA-N 0.000 claims 1
- VTTTXOGPYMPVPW-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(2,3-difluorophenyl)cyclobutyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C1=C(C(=CC=C1)F)F)F VTTTXOGPYMPVPW-UHFFFAOYSA-N 0.000 claims 1
- IONASXYPOBMBBE-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(2,4,5-trifluorophenyl)cyclobutyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C1=C(C=C(C(=C1)F)F)F)F IONASXYPOBMBBE-UHFFFAOYSA-N 0.000 claims 1
- ITYAJMHGAQGGOR-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(2,4-difluorophenyl)cyclobutyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C1=C(C=C(C=C1)F)F)F ITYAJMHGAQGGOR-UHFFFAOYSA-N 0.000 claims 1
- OLGXMCAJCVJOOS-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(2,4-difluorophenyl)cyclopropyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CC1)C1=C(C=C(C=C1)F)F)F OLGXMCAJCVJOOS-UHFFFAOYSA-N 0.000 claims 1
- AQSCSJFKJJCULX-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(2,5-difluorophenyl)cyclobutyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C1=C(C=CC(=C1)F)F)F AQSCSJFKJJCULX-UHFFFAOYSA-N 0.000 claims 1
- YPLIKXPJWPAMHH-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(2-fluorophenyl)cyclopropyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CC1)C1=C(C=CC=C1)F)F YPLIKXPJWPAMHH-UHFFFAOYSA-N 0.000 claims 1
- CVFUNOSWWHZQPL-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(2-methoxyphenyl)cyclopropyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CC1)C1=C(C=CC=C1)OC)F CVFUNOSWWHZQPL-UHFFFAOYSA-N 0.000 claims 1
- XJILLSGCZRFZGN-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(2-methylphenyl)cyclopropyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CC1)C1=C(C=CC=C1)C)F XJILLSGCZRFZGN-UHFFFAOYSA-N 0.000 claims 1
- GWHHJXUXHJKYOF-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(3,4-difluorophenyl)cyclobutyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C1=CC(=C(C=C1)F)F)F GWHHJXUXHJKYOF-UHFFFAOYSA-N 0.000 claims 1
- TWHOWWKLLANQQY-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(3,5-difluorophenyl)cyclobutyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C1=CC(=CC(=C1)F)F)F TWHOWWKLLANQQY-UHFFFAOYSA-N 0.000 claims 1
- YVEQMFKNMMXIMZ-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(3,5-difluorophenyl)cyclopropyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CC1)C1=CC(=CC(=C1)F)F)F YVEQMFKNMMXIMZ-UHFFFAOYSA-N 0.000 claims 1
- HCTAUPUREYXKFK-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(3-fluorophenyl)cyclopropyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CC1)C1=CC(=CC=C1)F)F HCTAUPUREYXKFK-UHFFFAOYSA-N 0.000 claims 1
- LTPUXKCCKVVLJB-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(3-methoxyphenyl)cyclopropyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CC1)C1=CC(=CC=C1)OC)F LTPUXKCCKVVLJB-UHFFFAOYSA-N 0.000 claims 1
- QXCJONADAMMDRA-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(3-methylphenyl)cyclobutyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C=1C=C(C=CC=1)C)F QXCJONADAMMDRA-UHFFFAOYSA-N 0.000 claims 1
- DNRQRGVRWPIVBO-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(4-fluoro-3-morpholin-4-ylphenyl)cyclobutyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C1=CC(=C(C=C1)F)N1CCOCC1)F DNRQRGVRWPIVBO-UHFFFAOYSA-N 0.000 claims 1
- NJAAVNSOZGGXFC-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(4-fluorophenyl)cyclopropyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CC1)C1=CC=C(C=C1)F)F NJAAVNSOZGGXFC-UHFFFAOYSA-N 0.000 claims 1
- XTEWTDPLEBUYHB-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(4-methoxyphenyl)cyclopropyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CC1)C1=CC=C(C=C1)OC)F XTEWTDPLEBUYHB-UHFFFAOYSA-N 0.000 claims 1
- GDYIQRPIWKNMRD-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(4-methylphenyl)cyclobutyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C1=CC=C(C=C1)C)F GDYIQRPIWKNMRD-UHFFFAOYSA-N 0.000 claims 1
- UHSNPYZGKQHYNH-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(4-morpholin-4-ylphenyl)cyclobutyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C1=CC=C(C=C1)N1CCOCC1)F UHSNPYZGKQHYNH-UHFFFAOYSA-N 0.000 claims 1
- CKZHCKRAKJWEOT-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(4-piperidin-1-ylphenyl)cyclobutyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C1=CC=C(C=C1)N1CCCCC1)F CKZHCKRAKJWEOT-UHFFFAOYSA-N 0.000 claims 1
- GRJVDOLELSBCEX-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-[(4-methylphenyl)sulfonylmethyl]cyclobutyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)CS(=O)(=O)C1=CC=C(C)C=C1)F GRJVDOLELSBCEX-UHFFFAOYSA-N 0.000 claims 1
- BBIYXQBIVALMDC-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-[2-(trifluoromethoxy)phenyl]cyclobutyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C1=C(C=CC=C1)OC(F)(F)F)F BBIYXQBIVALMDC-UHFFFAOYSA-N 0.000 claims 1
- MGMSBHAPWDRJFO-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-[2-(trifluoromethyl)phenyl]cyclobutyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C1=C(C=CC=C1)C(F)(F)F)F MGMSBHAPWDRJFO-UHFFFAOYSA-N 0.000 claims 1
- RQQKXOMZYCDEAI-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-[3-(trifluoromethyl)phenyl]cyclobutyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C1=CC(=CC=C1)C(F)(F)F)F RQQKXOMZYCDEAI-UHFFFAOYSA-N 0.000 claims 1
- JUEKLLPPPOBEDZ-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-[3-(trifluoromethyl)phenyl]cyclopropyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CC1)C1=CC(=CC=C1)C(F)(F)F)F JUEKLLPPPOBEDZ-UHFFFAOYSA-N 0.000 claims 1
- LETBEEUWGHYDCD-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-[3-[1-(oxetan-3-yl)piperidin-4-yl]phenyl]cyclobutyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C1=CC(=CC=C1)C1CCN(CC1)C1COC1)F LETBEEUWGHYDCD-UHFFFAOYSA-N 0.000 claims 1
- PCZZOFAJXJOFNY-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-[4-(1-ethylpiperidin-4-yl)phenyl]cyclobutyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C1=CC=C(C=C1)C1CCN(CC1)CC)F PCZZOFAJXJOFNY-UHFFFAOYSA-N 0.000 claims 1
- QPHSBZGOPPCSOU-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-[4-(1-propan-2-ylpiperidin-4-yl)phenyl]cyclobutyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C1=CC=C(C=C1)C1CCN(CC1)C(C)C)F QPHSBZGOPPCSOU-UHFFFAOYSA-N 0.000 claims 1
- HUINJMVBFMZLCP-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-[4-(trifluoromethoxy)phenyl]cyclobutyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C1=CC=C(C=C1)OC(F)(F)F)F HUINJMVBFMZLCP-UHFFFAOYSA-N 0.000 claims 1
- FUYRLGWIEZIQTN-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-[4-(trifluoromethyl)phenyl]cyclobutyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C1=CC=C(C=C1)C(F)(F)F)F FUYRLGWIEZIQTN-UHFFFAOYSA-N 0.000 claims 1
- FASUTFGXOCYZBQ-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-[4-(trifluoromethyl)phenyl]cyclopropyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CC1)C1=CC=C(C=C1)C(F)(F)F)F FASUTFGXOCYZBQ-UHFFFAOYSA-N 0.000 claims 1
- HMKSUSGISGIFSI-UHFFFAOYSA-N 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-[4-[1-(oxetan-3-yl)piperidin-4-yl]phenyl]cyclobutyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C1=CC=C(C=C1)C1CCN(CC1)C1COC1)F HMKSUSGISGIFSI-UHFFFAOYSA-N 0.000 claims 1
- GARYREBVDMJCRV-UHFFFAOYSA-N 5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-[3-(trifluoromethyl)phenyl]cyclobutyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C1=CC(=CC=C1)C(F)(F)F)(F)F GARYREBVDMJCRV-UHFFFAOYSA-N 0.000 claims 1
- WDUXNNMYTUAJJQ-UHFFFAOYSA-N 5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-[3-(trifluoromethyl)phenyl]cyclopropyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CC1)C1=CC(=CC=C1)C(F)(F)F)(F)F WDUXNNMYTUAJJQ-UHFFFAOYSA-N 0.000 claims 1
- IJSJQXPMPNDIIC-UHFFFAOYSA-N 5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-[4-(trifluoromethyl)phenyl]cyclobutyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCC1)C1=CC=C(C=C1)C(F)(F)F)(F)F IJSJQXPMPNDIIC-UHFFFAOYSA-N 0.000 claims 1
- UJBRSDCZMCQVNW-UHFFFAOYSA-N 5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-[4-(trifluoromethyl)phenyl]cyclopropyl]pyrimidin-2-amine Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CC1)C1=CC=C(C=C1)C(F)(F)F)(F)F UJBRSDCZMCQVNW-UHFFFAOYSA-N 0.000 claims 1
- KUGFHFYSHFZPPF-UHFFFAOYSA-N N-(1-benzylcyclobutyl)-5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound C(C1=CC=CC=C1)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)F KUGFHFYSHFZPPF-UHFFFAOYSA-N 0.000 claims 1
- MFIHEGPDEQFOMI-UHFFFAOYSA-N N-(1-phenylcyclohexyl)-5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound C1(=CC=CC=C1)C1(CCCCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)(F)F MFIHEGPDEQFOMI-UHFFFAOYSA-N 0.000 claims 1
- DLEMEQJHPARSIQ-UHFFFAOYSA-N N-(1-phenylcyclopentyl)-5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound C1(=CC=CC=C1)C1(CCCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)(F)F DLEMEQJHPARSIQ-UHFFFAOYSA-N 0.000 claims 1
- WVPNPRFAWODGFM-UHFFFAOYSA-N N-(1-phenylcyclopropyl)-5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound C1(=CC=CC=C1)C1(CC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)(F)F WVPNPRFAWODGFM-UHFFFAOYSA-N 0.000 claims 1
- RHMGLHIELWVWNJ-UHFFFAOYSA-N N-(1-pyridin-2-ylcyclobutyl)-5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound N1=C(C=CC=C1)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)(F)F RHMGLHIELWVWNJ-UHFFFAOYSA-N 0.000 claims 1
- YHQNFWQAKZFKIG-UHFFFAOYSA-N N-[1-(1,3-benzodioxol-5-yl)cyclobutyl]-5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound O1COC2=C1C=CC(=C2)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)F YHQNFWQAKZFKIG-UHFFFAOYSA-N 0.000 claims 1
- RRTGFNUETGDRKA-UHFFFAOYSA-N N-[1-(2,3-dichlorophenyl)cyclobutyl]-5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(2,6-difluorophenyl)cyclobutyl]pyrimidin-2-amine Chemical compound FC(F)c1nnc(o1)-c1cnc(NC2(CCC2)c2cccc(Cl)c2Cl)nc1.FC(F)c1nnc(o1)-c1cnc(NC2(CCC2)c2c(F)cccc2F)nc1 RRTGFNUETGDRKA-UHFFFAOYSA-N 0.000 claims 1
- KYWCGPOSIUFSLD-UHFFFAOYSA-N N-[1-(2,3-dichlorophenyl)cyclobutyl]-5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound ClC1=C(C=CC=C1Cl)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)(F)F KYWCGPOSIUFSLD-UHFFFAOYSA-N 0.000 claims 1
- BJTDKHDPIPKACC-UHFFFAOYSA-N N-[1-(2,4-dichlorophenyl)cyclobutyl]-5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound ClC1=C(C=CC(=C1)Cl)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)F BJTDKHDPIPKACC-UHFFFAOYSA-N 0.000 claims 1
- VDIYXBYZIDKWKJ-UHFFFAOYSA-N N-[1-(2,4-dichlorophenyl)cyclobutyl]-5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound ClC1=C(C=CC(=C1)Cl)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)(F)F VDIYXBYZIDKWKJ-UHFFFAOYSA-N 0.000 claims 1
- CJSUJTZKCPPBIK-UHFFFAOYSA-N N-[1-(2,4-difluorophenyl)cyclobutyl]-5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound FC1=C(C=CC(=C1)F)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)(F)F CJSUJTZKCPPBIK-UHFFFAOYSA-N 0.000 claims 1
- USFXGENGNCEDHZ-UHFFFAOYSA-N N-[1-(2,6-dichlorophenyl)cyclobutyl]-5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound ClC1=C(C(=CC=C1)Cl)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)F USFXGENGNCEDHZ-UHFFFAOYSA-N 0.000 claims 1
- UCEGNWNOCDDCHY-UHFFFAOYSA-N N-[1-(2-chloro-4-fluorophenyl)cyclobutyl]-5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound ClC1=C(C=CC(=C1)F)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)F UCEGNWNOCDDCHY-UHFFFAOYSA-N 0.000 claims 1
- ZPVWUBFDHSAQHI-UHFFFAOYSA-N N-[1-(2-chloro-4-fluorophenyl)cyclobutyl]-5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound ClC1=C(C=CC(=C1)F)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)(F)F ZPVWUBFDHSAQHI-UHFFFAOYSA-N 0.000 claims 1
- ANOJJASEQGNTMP-UHFFFAOYSA-N N-[1-(2-chloro-5-fluorophenyl)cyclobutyl]-5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound ClC1=C(C=C(C=C1)F)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)F ANOJJASEQGNTMP-UHFFFAOYSA-N 0.000 claims 1
- FBBSTBQBIACVCE-UHFFFAOYSA-N N-[1-(2-chloro-5-fluorophenyl)cyclobutyl]-5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound ClC1=C(C=C(C=C1)F)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)(F)F FBBSTBQBIACVCE-UHFFFAOYSA-N 0.000 claims 1
- DILYZXMTJRVDOS-UHFFFAOYSA-N N-[1-(2-chlorophenyl)cyclobutyl]-5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound ClC1=C(C=CC=C1)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)(F)F DILYZXMTJRVDOS-UHFFFAOYSA-N 0.000 claims 1
- VEXKDMWBSMXQDS-UHFFFAOYSA-N N-[1-(2-fluorophenyl)cyclobutyl]-5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound FC1=C(C=CC=C1)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)(F)F VEXKDMWBSMXQDS-UHFFFAOYSA-N 0.000 claims 1
- DYDSYHHBSABPIC-UHFFFAOYSA-N N-[1-(2-methylphenyl)cyclobutyl]-5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound C1(=C(C=CC=C1)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)(F)F)C DYDSYHHBSABPIC-UHFFFAOYSA-N 0.000 claims 1
- MTYSEJFZQATPIA-UHFFFAOYSA-N N-[1-(3,4-dichlorophenyl)cyclobutyl]-5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound ClC=1C=C(C=CC=1Cl)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)F MTYSEJFZQATPIA-UHFFFAOYSA-N 0.000 claims 1
- HORCJDGLBNSYHG-UHFFFAOYSA-N N-[1-(3,4-dichlorophenyl)cyclobutyl]-5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound ClC=1C=C(C=CC=1Cl)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)(F)F HORCJDGLBNSYHG-UHFFFAOYSA-N 0.000 claims 1
- NFYGXZGDNBEESM-UHFFFAOYSA-N N-[1-(3,4-difluorophenyl)cyclopropyl]-5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound FC=1C=C(C=CC=1F)C1(CC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)(F)F NFYGXZGDNBEESM-UHFFFAOYSA-N 0.000 claims 1
- QEOWLDIVBPNHRL-UHFFFAOYSA-N N-[1-(3-chloro-2-fluorophenyl)cyclobutyl]-5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound ClC=1C(=C(C=CC=1)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)F)F QEOWLDIVBPNHRL-UHFFFAOYSA-N 0.000 claims 1
- IUOXFJPHMTYLQM-UHFFFAOYSA-N N-[1-(3-chloro-2-fluorophenyl)cyclobutyl]-5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound ClC=1C(=C(C=CC=1)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)(F)F)F IUOXFJPHMTYLQM-UHFFFAOYSA-N 0.000 claims 1
- NWZNBJWNRCSQBE-UHFFFAOYSA-N N-[1-(3-chloro-4-fluorophenyl)cyclobutyl]-5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound ClC=1C=C(C=CC=1F)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)F NWZNBJWNRCSQBE-UHFFFAOYSA-N 0.000 claims 1
- DHBILDQTSYOIEV-UHFFFAOYSA-N N-[1-(3-chloro-4-fluorophenyl)cyclobutyl]-5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound ClC=1C=C(C=CC=1F)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)(F)F DHBILDQTSYOIEV-UHFFFAOYSA-N 0.000 claims 1
- AQOFANAUUDCBKJ-UHFFFAOYSA-N N-[1-(3-chloro-4-fluorophenyl)cyclopropyl]-5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound ClC=1C=C(C=CC=1F)C1(CC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)F AQOFANAUUDCBKJ-UHFFFAOYSA-N 0.000 claims 1
- TXFJULKRGRKKBX-UHFFFAOYSA-N N-[1-(3-chloro-4-fluorophenyl)cyclopropyl]-5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound ClC=1C=C(C=CC=1F)C1(CC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)(F)F TXFJULKRGRKKBX-UHFFFAOYSA-N 0.000 claims 1
- CAJWCPZUGRFFII-UHFFFAOYSA-N N-[1-(3-chlorophenyl)cyclopropyl]-5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound ClC=1C=C(C=CC=1)C1(CC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)F CAJWCPZUGRFFII-UHFFFAOYSA-N 0.000 claims 1
- FOOIEDFPEATDRX-UHFFFAOYSA-N N-[1-(3-chlorophenyl)cyclopropyl]-5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound ClC=1C=C(C=CC=1)C1(CC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)(F)F FOOIEDFPEATDRX-UHFFFAOYSA-N 0.000 claims 1
- YSSNGWHLVNKHHO-UHFFFAOYSA-N N-[1-(3-fluorophenyl)cyclobutyl]-5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound FC=1C=C(C=CC=1)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)(F)F YSSNGWHLVNKHHO-UHFFFAOYSA-N 0.000 claims 1
- LKCZVQWCRYUZRP-UHFFFAOYSA-N N-[1-(3-fluorophenyl)cyclopropyl]-5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound FC=1C=C(C=CC=1)C1(CC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)(F)F LKCZVQWCRYUZRP-UHFFFAOYSA-N 0.000 claims 1
- GLGYLUSYCAAOCR-UHFFFAOYSA-N N-[1-(3-methoxyphenyl)cyclobutyl]-5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound COC=1C=C(C=CC=1)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)(F)F GLGYLUSYCAAOCR-UHFFFAOYSA-N 0.000 claims 1
- KXMQNGWTEHPMCL-UHFFFAOYSA-N N-[1-(3-methylphenyl)cyclobutyl]-5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound C1(=CC(=CC=C1)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)(F)F)C KXMQNGWTEHPMCL-UHFFFAOYSA-N 0.000 claims 1
- PHSJJZPJMHPELO-UHFFFAOYSA-N N-[1-(4-chloro-2-fluorophenyl)cyclopropyl]-5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound ClC1=CC(=C(C=C1)C1(CC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)F)F PHSJJZPJMHPELO-UHFFFAOYSA-N 0.000 claims 1
- PXYOOEUTEMLNID-UHFFFAOYSA-N N-[1-(4-chloro-3-fluorophenyl)cyclopropyl]-5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound ClC1=C(C=C(C=C1)C1(CC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)F)F PXYOOEUTEMLNID-UHFFFAOYSA-N 0.000 claims 1
- SNLWPIMERWXFRG-UHFFFAOYSA-N N-[1-(4-chlorophenyl)cyclobutyl]-5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound ClC1=CC=C(C=C1)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)(F)F SNLWPIMERWXFRG-UHFFFAOYSA-N 0.000 claims 1
- ZIUJMIMQYVVZGH-UHFFFAOYSA-N N-[1-(4-chlorophenyl)cyclopropyl]-5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound ClC1=CC=C(C=C1)C1(CC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)F ZIUJMIMQYVVZGH-UHFFFAOYSA-N 0.000 claims 1
- IPVHWOPJHNWBSU-UHFFFAOYSA-N N-[1-(4-chlorophenyl)cyclopropyl]-5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound ClC1=CC=C(C=C1)C1(CC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)(F)F IPVHWOPJHNWBSU-UHFFFAOYSA-N 0.000 claims 1
- NRCQGFNPSMFQOI-UHFFFAOYSA-N N-[1-(4-fluorophenyl)cyclobutyl]-5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound FC1=CC=C(C=C1)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)(F)F NRCQGFNPSMFQOI-UHFFFAOYSA-N 0.000 claims 1
- ARYKQXKNKUHZAZ-UHFFFAOYSA-N N-[1-(4-fluorophenyl)cyclopropyl]-5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound FC1=CC=C(C=C1)C1(CC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)(F)F ARYKQXKNKUHZAZ-UHFFFAOYSA-N 0.000 claims 1
- FUVHFPCZSNPAMU-UHFFFAOYSA-N N-[1-(4-methoxyphenyl)cyclobutyl]-5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound COC1=CC=C(C=C1)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)(F)F FUVHFPCZSNPAMU-UHFFFAOYSA-N 0.000 claims 1
- ZKQXNUQBMYRAOQ-UHFFFAOYSA-N N-[1-(4-methylphenyl)cyclobutyl]-5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound C1(=CC=C(C=C1)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)(F)F)C ZKQXNUQBMYRAOQ-UHFFFAOYSA-N 0.000 claims 1
- SJXWGDHDJLRCIY-UHFFFAOYSA-N N-[1-(5-chloro-2-fluorophenyl)cyclobutyl]-5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound ClC=1C=CC(=C(C=1)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)F)F SJXWGDHDJLRCIY-UHFFFAOYSA-N 0.000 claims 1
- QNSFACIJYXXLCA-UHFFFAOYSA-N N-[1-(5-chloro-2-fluorophenyl)cyclobutyl]-5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound ClC=1C=CC(=C(C=1)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)(F)F)F QNSFACIJYXXLCA-UHFFFAOYSA-N 0.000 claims 1
- NFGWXLVQOGXBHC-UHFFFAOYSA-N N-[1-[2-(trifluoromethoxy)phenyl]cyclobutyl]-5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-amine Chemical compound FC(OC1=C(C=CC=C1)C1(CCC1)NC1=NC=C(C=N1)C=1OC(=NN=1)C(F)(F)F)(F)F NFGWXLVQOGXBHC-UHFFFAOYSA-N 0.000 claims 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- KMKHQBZYSIKMMY-UHFFFAOYSA-N benzyl 4-[[5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]pyrimidin-2-yl]amino]-4-phenylpiperidine-1-carboxylate Chemical compound FC(C1=NN=C(O1)C=1C=NC(=NC=1)NC1(CCN(CC1)C(=O)OCC1=CC=CC=C1)C1=CC=CC=C1)F KMKHQBZYSIKMMY-UHFFFAOYSA-N 0.000 claims 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
- C07C211/35—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing only non-condensed rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Claims (10)
1. Oksadiazol aminski spoj derivat predstavljen sljedećom formulom I, stereoizomer istog ili farmaceutski prihvatljiva sol istog:
[image]
pri čemu R1 je -CF2H ili -CF3;
L1 i L2 su svaki nezavisno -(C1-C2 alkilen)- ili veza;
Z1 do Z4 su svaki nezavisno N ili CRZ {pri čemu tri ili više od Z1 do Z4 ne može biti N u isto vreme}, pri čemu RZ je -H, -F, -Cl, -Br, -I ili -O(C1-C4 alkil);
R2 je -H ili -(C1-C4 alkil);
Y1 je -CH2-, -NRc-, -O-, -C(=O)- ili -S(=O)2-, pri čemu Rc je -H, -(C1-C6 alkil), -(C1-C4 alkil)-OH, -(C1-C4 alkil)-O-(C1-C4 alkil), -C(=O)-(C1-C4 alkil), -C(=O)-O(C1-C4 alkil), -C(=O)-O(C1-C4 alkil)-aril, -(C1-C4 alkil)-C(=O)-O(C1-C4 alkil), -S(=O)2-(C1-C4 alkil), aril, -(C1-C4 alkil)-aril, -(C2-C4 alkenil)-aril, heteroaril, -(C1-C4 alkil)-heteroaril, -C(=O)-(C3-C7 cikloalkil), -(C2-C6 heterocikloalkil) ili -(C1-C4 alkil)-C(=O)-(C2-C6 heterocikloalkil), {pri čemu najmanje jedan H od -(C1-C6 alkil), -(C1-C4 alkil)-OH, -(C1-C4 alkil)-O-(C1-C4 alkil), -C(=O)-(C1-C4 alkil), -C(=O)-O(C1-C4 alkil), -C(=O)-O(C1-C4 alkil)-aril, -(C1-C4 alkil)-C(=O)-O(C1-C4 alkil), -S(=O)2-(C1-C4 alkil), aril, -(C1-C4 alkil)-aril, (C2-C4 alkenil)-aril, heteroaril, -(C1-C4 alkil)-heteroaril, -C(=O)-(C3-C7 cikloalkil), -C2-C6 heterocikloalkil ili -(C1-C4 alkil)-C(=O)-(C2-C6 heterocikloalkil) može biti supstituiran sa -X };
a i b su svaki nezavisno cijeli broj 0, 1, 2, 3 ili 4 {pri čemu a i b ne mogu svi biti 0};
L3 je -(C1-C2 alkilen)-, -SO2-, -(C1-C2 alkilen)-SO2-, ili veza;
[image]
je -aril, -heteroaril,
[image]
ili heterocikloalkil, pri čemu Z5 i Z6 su svaki nezavisno -CH2- ili -O-; i
R4 do R6 su svaki nezavisno -H, -F, -Cl, -Br, -I, -OH, -O(C1-C4 alkil), -(C1-C4 alkil), -CF3, -OCF3, heterocikloalkil {pri čemu heterocikloalkil može biti nesupstituiran ili supstituiran sa C1-C4 alkilom ili heterocikloalkilom},
[image]
-O-aril, -CF2H, -C(=O)-(C1-C4 alkil), -C(=O)-O(C1-C4 alkil), -NRARB, -C(=O)-NRARB ili -S(=O)2-(C1-C4 alkil), pri čemu Y2 je -CH2-, -O-, -C(=O)- ili -S(=O)2-, Y3 do Y5 su svaki nezavisno -CH- ili -N-, i c do f su svaki nezavisno cijeli broj 0, 1, 2, 3 ili 4{pri čemu c i e ne mogu svi biti 0, i d i f ne mogu svi biti 0}, pri čemu RA i RB su svaki nezavisno -H ili -(C1-C4 alkil) {pri čemu najmanje jedan H od -(C1-C4 alkil) može biti supstituiran sa -X ili -OH},
pri čemu X je F, Cl, Br ili I.
2. Oksadiazol aminski spoj derivat predstavljen formulom I, stereoizomer istog ili farmaceutski prihvatljiva sol istog prema patentnom zahtjevu 1,
pri čemu R1 je -CF2H ili -CF3;
L1 i L2 su veza;
Z1 i Z3 su N;
Z2 i Z4 su CRZ, pri čemu RZ je -H, -F, -Cl, -Br, -I ili -O(C1-C4 alkil);
R2 je -H ili -(C1-C4 alkil);
Y1 je -CH2- ili -NRc-, pri čemu Rc je -H, ili -C(=O)-O(C1-C4 alkil)-aril {pri čemu najmanje jedan H od -C(=O)-O(C1-C4 alkil)-aril može biti supstituiran sa -X, pri čemu X je F, Cl, Br ili I};
a i b su svaki nezavisno cijeli broj 0, 1, 2 ili 3 {pri čemu a i b ne mogu svi biti 0};
L3 je -(C1-C2 alkilen)-, (C1-C2 alkilen)-SO2-, ili veza;
[image]
je fenil, piridin, benzo[d][1,3]dioksol, tiofen, pirimidin, pirazin ili piridazin; i
R4 do R6 su svaki nezavisno -H, -F, -Cl, -Br, -I, -OH, -O(C1-C4 alkil), -(C1-C4 alkil), -CF3, -OCF3, piperidin, morfolino, piperazin ili pirolidin {pri čemu piperidin, morfolino, piperazin ili pirolidin mogu biti nesupstituirani ili supstituirani sa C1-C4 alkilom}, ili
[image]
pri čemu Y2 je -O-. Y3 i Y5 su -CH-. Y4 je -N-. c i e su svaki nezavisno cijeli broj 0, 1 ili 2 {pri čemu c i e ne mogu svi biti 0}, i d i f su svaki nezavisno cijeli broj 0, 1, 2 ili 3 {pri čemu d i f ne mogu svi biti 0}.
3. Oksadiazol aminski spoj derivat predstavljen formulom I, stereoizomer istog ili farmaceutski prihvatljiva sol istog prema patentnom zahtjevu 1,
pri čemu spoj predstavljen gore spomenutom formulom I je spoj predstavljen sljedećom formulom II :
[image]
pri čemu R1 je -CF2H ili -CF3;
R2 je -H;
Y1 je -CH2- ili -NRc-, pri čemu Rc je -H, ili -C(=O)-O(C1-C4 alkil)-aril;
a i b su svaki nezavisno cijeli broj 0, 1, 2 ili 3 {pri čemu a i b ne mogu svi biti 0}, L3 je -(C1-C2 alkilen)-, (C1-C2 alkilen)-SO2-, ili veza;
[image]
je fenil, piridin, benzo[d][1,3]dioksol ili tiofen; i
R4 do R6 su svaki nezavisno -H, -F, -Cl, -Br, -I, -OH, -O(C1-C4 alkil), -(C1-C4 alkil), -CF3, -OCF3, piperidin, morfolino {pri čemu piperidin može biti nesupstituiran ili supstituiran sa C1-C4 alkilom}, ili
[image]
4. Oksadiazol aminski spoj derivat predstavljen formulom II, stereoizomer istog ili farmaceutski prihvatljiva sol istog prema patentnom zahtjevu 3,
pri čemu R1 je -CF2H ili -CF3;
R2 je -H;
Y1 je -CH2- ili -NRc-, pri čemu Rc je -H, ili
[image]
a i b su svaki nezavisno cijeli broj 0, 1, 2 ili 3 {pri čemu a i b ne mogu svi biti 0, prsten formiran sa Y1, a i b je 3- do 7-člani zasićeni cikloalkil kada Y1 je-CH2- ili prsten formiran sa Y1, a i b je 3- do 7-člani zasićeni heterocikloalkil koji sadrži jedan N kada Y1 je -NRc-};
L3 je -CH2-, - CH2-SO2-, ili veza;
[image]
je fenil, piridin, benzo[d][1,3]dioksol ili tiofen; i
R4 do R6 su svaki nezavisno -H, -F, -Cl, -Br, -I, -OH, -O(C1-C4 alkil), -(C1-C4 alkil), -CF3, -OCF3, morfolino,
[image]
ili
[image]
pri čemu R7 je -H ili -(C1-C4 alkil).
5. Oksadiazol aminski spoj derivat predstavljen formulom I, stereoizomer istog ili farmaceutski prihvatljiva sol istog prema patentnom zahtjevu 1,
pri čemu spoj sa formulom I je odabran iz grupe koja se sastoji od sljedećih spojeva :
5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(1-fenilciklopropil)pirimidin-2-amina;
N-(1-fenilciklopropil)-5-(5-(trifluorometil)-1,3,4-oksadiazol-2-il)pirimidin-2-amina;
5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(1-fenilciklobutil)pirimidin-2-amina;
5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(1-fenilciklopentil)pirimidin-2-amina;
N-(1-fenilciklopentil)-5-(5-(trifluorometil)-1,3,4-oksadiazol-2-il)pirimidin-2-amina;
5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(1-fenilcikloheksil)pirimidin-2-amina;
N-(1-fenilcikloheksil)-5-(5-(trifluorometil)-1,3,4-oksadiazol-2-il)pirimidin-2-amina;
5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(1-(4-metoksifenil)ciklobutil)pirimidin-2-amina;
N-(1-(4-metoksifenil)ciklobutil)-5-(5-(trifluorometil)-1,3,4-oksadiazol-2-il)pirimidin-2-amina;
5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(1-(3-metoksifenil)ciklobutil)pirimidin-2-amina;
N-(1-(3-metoksifenil)ciklobutil)-5-(5-(trifluorometil)-1,3,4-oksadiazol-2-il)pirimidin-2-amina;
5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(1-(3-fluorofenil)ciklobutil)pirimidin-2-amina;
N-(1-(3-fluorofenil)ciklobutil)-5-(5-(trifluorometil)-1,3,4-oksadiazol-2-il)pirimidin-2-amina;
5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(1-(2-fluorofenil)ciklobutil)pirimidin-2-amina;
N-(1-(2-fluorofenil)ciklobutil)-5-(5-(trifluorometil)-1,3,4-oksadiazol-2-il)pirimidin-2-amina;
5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(1-(4-fluorofenil)ciklobutil)pirimidin-2-amina;
N-(1-(4-fluorofenil)ciklobutil)-5-(5-(trifluorometil)-1,3,4-oksadiazol-2-il)pirimidin-2-amina;
N-(1-(2-klorofenil)ciklobutil)-5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)pirimidin-2-amina;
N-(1-(3-klorofenil)ciklobutil)-5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)pirimidin-2-amina;
N-(1-(4-klorofenil)ciklobutil)-5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)pirimidin-2-amina;
N-(1-(2-klorofenil)ciklobutil)-5-(5-(trifluorometil)-1,3,4-oksadiazol-2-il)pirimidin-2-amina ;
N-(1-(4-klorofenil)ciklobutil)-5-(5-(trifluorometil)-1,3,4-oksadiazol-2-il)pirimidin-2-amina;
5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(1-(piridin-2-il)ciklobutil)pirimidin-2-amina;
N-(1-(piridin-2-il)ciklobutil)-5-(5-(trifluorometil)-1,3,4-oksadiazol-2-il)pirimidin-2-amina;
5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(1-(3-(trifluorometil)fenil)ciklobutil)pirimidin-2-amin;
5-(5-(trifluorometil)-1,3,4-oksadiazol-2-il)-N-(1-(3-(trifluorometil)fenil)ciklobutil)pirimidin-2-amina;
5-(S-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(1-(o-tolil)ciklobutil)pirimidin-2-amina;
N-(1-(o-tolil)ciklobutil)-5-(5-(trifluorometil)-1,3,4-oksadiazol-2-il)pirimidin-2-amina;
5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(1-(m-tolil)ciklobutil)pirimidin-2-amina;
N-(1-(m-tolil)ciklobutil)-5-(5-(trifluorometil)-1,3,4-oksadiazol-2-il)pirimidin-2-amina;
5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(1-(p-tolil)ciklobutil)pirimidin-2-amina;
N-(1-(p-tolil)ciklobutil)-5-(5-(trifluorometil)-1,3,4-oksadiazol-2-il)pirimidin-2-amina;
Benzil 4-((5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)pirimidin-2-il)amino)-4-fenilpiperidin-1 -karboksilata;
5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(4-fenilpiperidin-4-il)pirimidin-2-amina;
5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(1-(2-fluorofenil)ciklopropil)pirimidin-2-amina;
5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(1-(4-fluorofenil)ciklopropil)pirimidin-2-amina;
N-(1-(4-fluorofenil)ciklopropil)-5-(5-(trifluorometil)-1,3,4-oksadiazol-2-il)pirimidin-2-amina;
5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(1-(3-fluorofenil)ciklopropil)pirimidin-2-amina;
N-(1-(3-fluorofenil)ciklopropil)-5-(5-(trifluorometil)-1, 3,4-oksadiazol-2-il)pirimidin-2-amina;
N-(1-(3-kloro-4-fluorofenil)ciklopropil)-5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)pirimidin-2-amina;
N-(1-(3-kloro-4-fluorofenil)ciklopropil)-5-(5-(trifluorometil)-1,3,4-oksadiazol-2-il)pirimidin-2-amina;
5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(1-(4-(trifluorometil)fenil)ciklopropil)pirimidin-2-amina;
5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(1-(3-(trifluorometil)fenil)ciklopropil)pirimidin-2-amina;
5-(5-(trifluorometil)-1,3,4-oksadiazol-2-il)-N-(1-(3-(trifluorometil)fenil)ciklopropil)pirimidin-2-amina;
5-(5-(trifluorometil)-1,3,4-oksadiazol-2-il)-N-(1-(4-(trifluorometil)fenil)ciklopropil)pirimidin-2-amina;
3-(1-((5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)pirimidin-2-il)amino)ciklobutil)fenola;
5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(1-(3,4-difluorofenil)ciklopropil)pirimidin-2-amina;
N-(1-(3,4-difluorofenil)ciklopropil)-5-(5-(trifluorometil)-1,3,4-oksadiazol-2-il)pirimidin-2-amina;
N-(1-(3-kloro-4-fluorofenil)ciklobutil)-5-(5-(difluorometil)-1, 3,4-oksadiazol-2-il)pirimidin-2-amina;
N-(1-(3-kloro-4-fluorofenil)ciklobutil)-5-(5-(trifluorometil)-1,3,4-oksadiazol-2-il)pirimidin-2-amina;
5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(1-(3,5-difluorofenil)ciklobutil)pirimidin-2-amina;
N-(1-(benzo[d][1,3]dioksol-5-il)ciklobutil)-5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)pirimidin-2-amina;
5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(1-(2,5-difluorofenil)ciklobutil)pirimidin-2-amina;
5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(1-(4-(trifluorometoksi)fenil)ciklobutil)pirimidin-2-amina;
5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(1-(2,4,5-trifluorofenil)ciklobutil)pirimidin-2-amina;
5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(1-(2,3-difluorofenil)ciklobutil)pirimidin-2-amina;
5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(1-(2,6-difluorofenil)ciklobutil)pirimidin-2-amina
N-(1-(2,3-diklorofenil)ciklobutil)-5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)pirimidin-2-amina;
N-(1-(2,3-diklorofenil)ciklobutil)-5-(5-(trifluorometil)-1,3,4-oksadiazol-2-il)pirimidin-2-amina;
N-(1-(3,4-diklorofenil)ciklobutil)-5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)pirimidin-2-amina;
N-(1-(3,4-diklorofenil)ciklobutil)-5-(5-(trifluorometil)-1,3,4-oksadiazol-2-il)pirimidin-2-amina;
N-(1-(2,4-diklorofenil)ciklobutil)-5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)pirimidin-2-amina;
N-(1-(2,4-diklorofenil)ciklobutil)-5-(5-(trifluorometil)-1,3,4-oksadiazol-2-il)pirimidin-2-amina;
N-(1-(2,6-diklorofenil)ciklobutil)-5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)pirimidin-2-amina;
5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(1-(piridin-3-il)ciklobutil)pirimidin-2-amina;
N-(1-(2-kloro-4-fluorofenil}ciklobutil)-5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)pirimidin-2-amina;
N-(1-(2-kloro-4-fluorofenil)ciklobutil)-5-(5-(trifluorometil)-1,3,4-oksadiazol-2-il)pirimidin-2-amina;
N-(1-(2-kloro-5-fluorofenil)ciklobutil)-5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)pirimidin-2-amina;
N-(1-(2-kloro-5-fluorofenil)ciklobutil)-5-(5-(trifluorometil)-1,3,4-oksadiazol-2-il)pirimidin-2-amina;
N-(1-(5-kloro-2-fluorofenil)ciklobutil)-5-(5-(difluorometil)-1, 3,4-oksadiazol-2-il)pirimidin-2-amina;
N-(1-(5-kloro-2-fluorofenil)ciklobutil)-5-(5-(trifluorometil)-1,3,4-oksadiazol-2-il)pirimidin-2-amina;
N-(1-(3-kloro-2-fluorofenil)ciklobutil)-5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)pirimidin-2-amina;
N-(1-(3-kloro-2-fluorofenil)ciklobutil)-5-(5-(trifluorometil)-1,3,4-oksadiazol-2-il)pirimidin-2-amina;
5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(1-(4-(1-(oksetan-3-il)piperidin-4-il)fenil)ciklobutil)pirimidin-2-amina;
5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(1-(tosilmetil)ciklobutil)pirimidin-2-amina;
5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(1-(2,4-difluorofenil)ciklobutil)pirimidin-2-amina;
5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(1-(2-(trifluorometoksi)fenil)ciklobutil)pirimidin-2-amina;
N-(1-benzilciklobutil)-5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)pirimidin-2-amina;
N-(1-(2-(trifluorometoksi)fenil)ciklobutil)-5-(5-(trifluorometil)-1,3,4-oksadiazol-2-il)pirimidin-2-amina;
N-(1-(2,4-difluorofenil)ciklobutil)-5-(5-(trifluorometil)-1,3,4-oksadiazol-2-il)pirimidin-2-amina;
5-(5-(difluorometil)-1,3,4-oaadiazol-2-il)-N-(1-(4-(1-metilpiperidin-4-il)fenil)ciklobutil)pirimidin-2-amina;
5-(5-(difluorometil)-1, 3,4-oksadiazol-2-il)-N-(1-(4-{ 1-etilpiperidin-4-il)fenil)ciklobutil)pirimidin-2-amina;
5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(1-(4-(1-izopropilpiperidin-4-il)fenil)ciklobutil)pirimidin-2-amina;
5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(1-(tiofen-3-il)ciklobutil)pirimidin-2-amina;
5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(1-(tiofen-2-il)ciklopropil)pirimidin-2-amina;
5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(1-(4-(piperidin-1-il)fenil)ciklobutil)pirimidin-2-amina;
5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(1-(2-(trifluorometil)fenil)ciklobutil)pirimidin-2-amina;
5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(1-(4-(trifluorometil)fenil)ciklobutil)pirimidin-2-amina;
5-(5-(trifluorometil)-1,3,4-oksadiazol-2-il)-N-(1-(4-(trifluorometil)fenil)ciklobutil)pirimidin-2-amina;
5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(1-(3,4-difluorofenil)ciklobutil)pirimidin-2-amina;
5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(1-(4-fluoro-3-morfolinofenil)ciklobutil)pirimidin-2-amina;
5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(1-(2-metoksifenil)ciklopropil)pirimidin-2-amina;
5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(1-(3-metoksifenil)ciklopropil)pirimidin-2-amina;
5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(1-(4-metoksifenil)ciklopropil)pirimidin-2-amina;
N-(1-(3-klorofenil)ciklopropil)-5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)pirimidin-2-amina;
N-(1-(3-klorofenil)ciklopropil)-5-(5-(trifluorometil)-1,3,4-oksadiazol-2-il)pirimidin-2-amina;
N-(1-(4-klorofenil)ciklopropil)-5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)pirimidin-2-amina;
N-(1-(4-klorofenil)ciklopropil)-5-(5-(trifluorometil)-1,3,4-oksadiazol-2-il)pirimidin-2-amina;
N-(1-(4-kloro-3-fluorofenil)ciklopropil)-5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)pirimidin-2-amina;
5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(1-(o-tolil)ciklopropil)pirimidin-2-amina;
N-(1-(4-kloro-2-fluorofenil)ciklopropil)-5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)pirimidin-2-amina;
5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(1-(3,5-difluorofenil)ciklopropil)pirimidin-2-amina;
5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(1-(3,4-difluorofenil)ciklopropil)pirimidin-2-amina;
5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(1-(3-(1-(oksetan-3-il)piperidin-4-il)fenil)ciklobutil)pirimidin-2-amina;
5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(1-(2,4-difluorofenil)ciklopropil)pirimidin-2-amina; i
5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(1-(4-morfolinofenil)ciklobutil)pirimidin-2-amina.
6. Oksadiazol aminski spoj derivat predstavljen formulom I, stereoizomer istog ili farmaceutski prihvatljiva sol istog prema patentnom zahtjevu 5,
pri čemu spoj formule I je odabran iz grupe koja se sastoji od sljedećih spojeva :
5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(1-fenilciklopropil)pirimidin-2-amina;
5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(1-fenilciklobutil)pirimidin-2-amina;
5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(1-fenilciklopentil)pirimidin-2-amina;
5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(1-(4-metoksifenil)ciklobutil)pirimidin-2-amina;
5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(1-(3-metoksifenil)ciklobutil)pirimidin-2-amina;
5-(5-(difluorometil)-1,3,4-oksadiaaol-2-il)-N-(1-(3-fluorofenil)ciklobutil)pirimidin-2-amina;
5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(1-(2-fluorofenil)ciklobutil)pirimidin-2-amina;
5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(1-(4-fluorofenil)ciklobutil)pirimidin-2-amina;
N-(1-(2-klorofenil)ciklobutil)-5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)pirimidin-2-amina;
N-(1-(3-klorofenil)ciklobutil)-5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)pirimidin-2-amina;
N-(1-(4-klorofenil)ciklobutil)-5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)pirimidin-2-amina; i
5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(1-(piridin-2-il)ciklobutil)pirimidin-2-amina.
7. Oksadiazol aminski spoj derivat predstavljen formulom I, stereoizomer istog ili farmaceutski prihvatljiva sol istog prema patentnom zahtjevu 6,
pri čemu spoj formule I je odabran iz grupe koja se sastoji od sljedećih spojeva :
5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(1-fenilciklobutil)pirimidin-2-amina;
5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(1-(3-fluorofenil)ciklobutil)pirimidin-2-amina;
5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(1-(2-fluorofenil)ciklobutil)pirimidin-2-amina;
N-(1-(2-klorofenil)ciklobutil)-5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)pirimidin-2-amina;
N-(1-(3-klorofenil)ciklobutil)-5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)pirimidin-2-amina; i
5-(5-(difluorometil)-1,3,4-oksadiazol-2-il)-N-(1-(piridin-2-il)ciklobutil)pirimidin-2-amina.
8. Farmaceutska kompozicija koja sadrži spoj predstavljen formulom I, stereoizomer istog ili farmaceutski prihvatljiva sol istog prema bilo kojem od patentnih zahtjeva 1 do 7.
9. Farmaceutska kompozicija za primjenu u prevenciji ili liječenju bolesti posredovanih histonskom deacetilazom, koja sadrži spoj predstavljen formulom I, stereoizomer istog ili farmaceutski prihvatljivu sol istog prema bilo kojem od patentnih zahtjeva 1 do 7,
pri čemu bolest posredovana histonskom deacetilazom je odabrana od infektivnih bolesti; neoplazmi; endokrinih, nutritivnih i metaboličkih bolesti; mentalnih i poremećaja ponašanja; neuroloških bolesti; bolesti oka i adneksa; kardiovaskularnih bolesti; respiratornih bolesti; digestivnih bolesti; bolesti kože i potkožnog tkiva; bolesti mišićnokoštanog sustava i vezivnog tkiva; ili kongenitalnih malformacija, deformacija i kromosomalnih abnormalnosti.
10. Spoj predstavljen formulom I. stereoizomer istog ili farmaceutski prihvatljiva sol istog prema bilo kojem od patentnih zahtjeva 1 do 7 za primjenu u liječenju bolesti posredovanih histonskom deacetilazom,
pri čemu je bolest posredovana histonskom deacetilazom odabrana od infektivnih bolesti; neoplazmi; endokrinih, nutritivnih i metaboličkih bolesti; mentalnih i poremećaja ponašanja; neuroloških bolesti; bolesti oka i adneksa; kardiovaskularnih bolesti; respiratornih bolesti; digestivnih bolesti; bolesti kože i potkožnog tkiva; bolesti mišićnokoštanog sustava i vezivnog tkiva; ili kongenitalnih malformacija, deformacija i kromosomalnih abnormalnosti.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20150142014 | 2015-10-12 | ||
EP16855690.0A EP3362445B1 (en) | 2015-10-12 | 2016-10-11 | Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
PCT/KR2016/011355 WO2017065473A1 (en) | 2015-10-12 | 2016-10-11 | Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20230201T1 true HRP20230201T1 (hr) | 2023-03-31 |
Family
ID=58517488
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20230201TT HRP20230201T1 (hr) | 2015-10-12 | 2016-10-11 | Oksadiazol aminski spojevi derivati kao inhibitor histonske deacetilaze 6 i farmaceutska kompozicija koja sadrži iste |
Country Status (21)
Country | Link |
---|---|
US (1) | US10494355B2 (hr) |
EP (1) | EP3362445B1 (hr) |
JP (1) | JP6697074B2 (hr) |
KR (1) | KR101839137B1 (hr) |
CN (1) | CN108699048B (hr) |
AU (1) | AU2016338118B2 (hr) |
CA (1) | CA3001666C (hr) |
DK (1) | DK3362445T3 (hr) |
ES (1) | ES2940413T3 (hr) |
FI (1) | FI3362445T3 (hr) |
HR (1) | HRP20230201T1 (hr) |
HU (1) | HUE061967T2 (hr) |
MX (1) | MX2018004447A (hr) |
MY (1) | MY196174A (hr) |
NZ (1) | NZ740809A (hr) |
PH (1) | PH12018500773A1 (hr) |
PL (1) | PL3362445T3 (hr) |
PT (1) | PT3362445T (hr) |
RU (1) | RU2695133C1 (hr) |
TW (1) | TWI694073B (hr) |
WO (1) | WO2017065473A1 (hr) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016126726A1 (en) | 2015-02-02 | 2016-08-11 | Forma Therapeutics, Inc. | Bicyclic [4,6,0] hydroxamic acids as hdac6 inhibitors |
ES2903523T3 (es) | 2015-02-02 | 2022-04-04 | Valo Health Inc | Acidos 3-aril-4-amido-biciclico [4.5.0]hidroxámicos como inhibidores de HDAC |
US10538498B2 (en) | 2015-07-27 | 2020-01-21 | Chong Kun Dang Pharmaceutical Corp. | 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
MY190301A (en) | 2015-07-27 | 2022-04-13 | Chong Kun Dang Pharmaceutical Corp | 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same |
US10464911B2 (en) | 2015-07-27 | 2019-11-05 | Chong Kun Dang Pharmaceutical Corp. | 1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
DK3331864T3 (da) | 2015-08-04 | 2021-12-13 | Chong Kun Dang Pharmaceutical Corp | 1,3,4-Oxadiazolderivat-forbindelser som histon-deacetylase-6-hæmmer, og den farmaceutiske sammensætning omfattende disse |
KR101839137B1 (ko) | 2015-10-12 | 2018-03-26 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 옥사다이아졸 아민 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
EP3472131B1 (en) | 2016-06-17 | 2020-02-19 | Forma Therapeutics, Inc. | 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors |
US10357493B2 (en) | 2017-03-10 | 2019-07-23 | Selenity Therapeutics (Bermuda), Ltd. | Metalloenzyme inhibitor compounds |
KR102316234B1 (ko) | 2018-07-26 | 2021-10-22 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
UY38525A (es) | 2018-12-21 | 2020-07-31 | Bayer Ag | 1,3,4-oxadiazoles y derivados de éstos como nuevos agentes fungicidas |
WO2020158762A1 (ja) * | 2019-01-30 | 2020-08-06 | 武田薬品工業株式会社 | 複素環化合物 |
CN111848423B (zh) * | 2019-04-30 | 2022-10-14 | 尚科生物医药(上海)有限公司 | 3-氧代环丁基氨基甲酸叔丁酯的制备方法 |
JP2022552444A (ja) | 2019-09-27 | 2022-12-15 | 武田薬品工業株式会社 | Hdac6阻害剤として有用な2-イソインドール-1,3,4-オキサジアゾール誘導体 |
CN114980887A (zh) | 2019-12-20 | 2022-08-30 | 特纳亚治疗股份有限公司 | 氟代烷基-噁二唑及其用途 |
US11339150B2 (en) | 2019-12-27 | 2022-05-24 | Onkure, Inc. | Benzimidazole compounds as HDAC6 inhibitors |
UY39275A (es) | 2020-06-19 | 2022-01-31 | Bayer Ag | 1,3,4-oxadiazol pirimidinas como fungicidas, procesos e intermediarios para su preparación, métodos de uso y usos de los mismos |
UY39276A (es) | 2020-06-19 | 2022-01-31 | Bayer Ag | Uso de compuestos de 1,3,4–oxadiazol–2–ilpirimidina para controlar microorganismos fitopatógenos, métodos de uso y composiciones. |
UY39277A (es) | 2020-06-19 | 2022-01-31 | Bayer Ag | Combinación de compuestos activos, método y uso de las mismas para controlar microorganismos dañinos y semilla tratada |
BR112022025710A2 (pt) | 2020-06-19 | 2023-03-07 | Bayer Ag | 1,3,4-oxadiazol pirimidinas e 1,3,4-oxadiazol piridinas como fungicidas |
BR112022025692A2 (pt) | 2020-06-19 | 2023-02-28 | Bayer Ag | 1,3,4-oxadiazóis e seus derivados como fungicidas |
AU2021322052A1 (en) | 2020-08-07 | 2023-03-09 | Italfarmaco S.P.A. | 2-(4-((5-(benzo[b]thiophen-3-yl)-1H-tetrazol-1-yl)methyl)phenyl)-5-(difluoromethyl)-1,3,4-oxadiazole derivatives and similar compounds as selective inhibitors of histone deacetylase 6 (HDAC6) for use in treating e.g. peripheral neuropathy |
EP4308097A1 (en) * | 2021-03-15 | 2024-01-24 | The Regents Of The University Of Michigan | Non-hydroxamate hdac6 inhibitors and related methods of use |
CN117561059A (zh) | 2021-04-23 | 2024-02-13 | 特纳亚治疗股份有限公司 | 用于治疗扩张型心肌病的hdac6抑制剂 |
IL308152A (en) * | 2021-05-04 | 2024-01-01 | Tenaya Therapeutics Inc | 2-fluoroalkyl-4,3,1-oxadiazol-5-yl-thiazole, HDAC6 inhibitors for use in the treatment of metabolic disease and HFPEF |
CN117500785A (zh) | 2021-06-16 | 2024-02-02 | 细胞基因公司 | 用于治疗神经退化性疾病的含羧酸氮杂环丁烷基化合物 |
CN115572244B (zh) * | 2021-06-21 | 2024-04-30 | 复旦大学 | 2’-芳基查尔酮类化合物及其制备方法和在制药中的用途 |
WO2023196601A1 (en) * | 2022-04-08 | 2023-10-12 | Eikonizo Therapeutics, Inc. | Oxadiazole hdac6 inhibitors and uses thereof |
WO2024033293A1 (en) * | 2022-08-08 | 2024-02-15 | Italfarmaco S.P.A. | Difluoro- and trifluoro-acetyl hydrazides as selective hdac6 inhibitors |
CN115286615A (zh) * | 2022-09-01 | 2022-11-04 | 深圳市真味生物科技有限公司 | 一种消旋尼古丁的制备方法 |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0276432A3 (de) | 1986-12-12 | 1988-10-26 | Ciba-Geigy Ag | Schädlingsbekämpfungsmittel |
KR100265385B1 (ko) | 1998-02-27 | 2000-11-01 | 윤여표 | 순환기 질환의 예방 및 치료 효능을 갖는 홍경천 추출물 |
US6897220B2 (en) | 2001-09-14 | 2005-05-24 | Methylgene, Inc. | Inhibitors of histone deacetylase |
US7868204B2 (en) | 2001-09-14 | 2011-01-11 | Methylgene Inc. | Inhibitors of histone deacetylase |
BR0213129A (pt) | 2001-10-03 | 2004-08-10 | Pharmacia Corp | Pró-drogas de compostos policìclicos substituìdos, úteis para inibição seletiva da cascata da coagulação |
ATE430727T1 (de) | 2001-12-20 | 2009-05-15 | Bristol Myers Squibb Co | Alpha-(n-sulfonamid)acetamidderivate als beta- amyloidinhibitoren |
AU2006270322A1 (en) | 2005-07-14 | 2007-01-25 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
ES2431050T3 (es) | 2005-08-04 | 2013-11-22 | Sirtris Pharmaceuticals, Inc. | Benzotiazoles y tiazolopiridinas como moduladores de la sirtuína |
WO2007032445A1 (ja) * | 2005-09-16 | 2007-03-22 | Kyowa Hakko Kogyo Co., Ltd. | タンパク質キナーゼ阻害剤 |
EA015198B1 (ru) | 2006-03-23 | 2011-06-30 | Биота Юроп Лимитед | Антибактериальные агенты |
WO2007143822A1 (en) | 2006-06-14 | 2007-12-21 | Methylgene Inc. | Sulfamide and sulfamate derivatives as histone deacetylase inhibitors |
EP1878730A1 (en) | 2006-07-12 | 2008-01-16 | Bayer Schering Pharma Aktiengesellschaft | Substituted isoxazolines, pharmaceutical compositions containing the same, methods of preparing the same, and uses of the same |
CA2670707A1 (en) | 2006-12-11 | 2008-06-19 | Genentech, Inc. | Compositions and methods for treating a neoplasm |
JP5478488B2 (ja) | 2007-06-20 | 2014-04-23 | メルク・シャープ・アンド・ドーム・コーポレーション | Janusキナーゼの阻害剤 |
WO2009010479A2 (en) | 2007-07-13 | 2009-01-22 | Euroscreen S.A. | Heterocyclic methylene piperidine derivatives and their use |
KR100903743B1 (ko) | 2007-08-28 | 2009-06-19 | 전병태 | 소화기계 질환개선 및 예방용 식품 조성물 |
CA2698511C (en) | 2007-09-04 | 2016-10-11 | The Scripps Research Institute | Substituted pyrimidinyl-amines as protein kinase inhibitors |
CN101918389A (zh) | 2007-11-02 | 2010-12-15 | 梅特希尔基因公司 | 组蛋白脱乙酰酶抑制剂 |
EP2207811B1 (en) | 2007-11-02 | 2017-01-04 | Momenta Pharmaceuticals, Inc. | Non-anticoagulant polysaccharide compositions |
EP2321264B1 (en) | 2008-07-23 | 2016-05-04 | President and Fellows of Harvard College | Deacetylase inhibitors and uses thereof |
US20120136003A1 (en) | 2009-04-20 | 2012-05-31 | Institute For Oneworld Health | Compounds, compositions and methods comprising 1,3,4-oxadiazole derivatives |
WO2010126002A1 (ja) | 2009-04-28 | 2010-11-04 | 塩野義製薬株式会社 | ヘテロ環スルホンアミド化合物を含有する医薬 |
JP2011008205A (ja) | 2009-05-27 | 2011-01-13 | Fujifilm Corp | 二軸性光学異方性膜を作製するための組成物 |
US8981084B2 (en) | 2010-01-13 | 2015-03-17 | Tempero Pharmaceuticals, Inc. | Oxadiazole HDAC inhibitors |
WO2011088181A1 (en) | 2010-01-13 | 2011-07-21 | Tempero Pharmaceuticals, Inc. | Compounds and methods |
CN103108867A (zh) | 2010-02-25 | 2013-05-15 | 皮拉马尔企业有限公司 | 噁二唑化合物及其制备和用途 |
AR081331A1 (es) * | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
EP2569313A1 (en) * | 2010-05-12 | 2013-03-20 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
US8697739B2 (en) | 2010-07-29 | 2014-04-15 | Novartis Ag | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof |
RU2601550C2 (ru) | 2010-12-09 | 2016-11-10 | Вокхардт Лимитед | Кетолидные соединения |
KR101262870B1 (ko) | 2011-01-28 | 2013-05-09 | 환인제약 주식회사 | 호장근 추출물을 함유하는 호흡기 질환의 예방 또는 치료용 조성물 |
WO2013008162A1 (en) | 2011-07-08 | 2013-01-17 | Novartis Ag | Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease |
US9512083B2 (en) | 2011-07-20 | 2016-12-06 | The General Hospital Corporation | Histone deacetylase 6 selective inhibitors for the treatment of bone disease |
WO2013066833A1 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods to inhibit histone deacetylase (hdac) enzymes |
WO2013066835A2 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
WO2013066839A2 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
EP2785713B1 (en) | 2011-11-28 | 2016-09-07 | Novartis AG | Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease |
EP2785720B1 (en) | 2011-11-29 | 2017-08-09 | Nanjing Allgen Pharma Co. Ltd. | Heterocyclic amides compounds which are hdac6 inhibitors and used as anti-tumoral agents |
EP3385257A1 (en) | 2013-09-06 | 2018-10-10 | Aurigene Discovery Technologies Limited | 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators |
US9650379B2 (en) | 2013-12-12 | 2017-05-16 | Chong Kun Dang Pharmaceutical Corp. | Azaindole derivatives as selective histone deacetylase (HDAC) inhibitors and pharmaceutical compositions comprising the same |
CN104744446B (zh) | 2013-12-30 | 2019-06-25 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
EP3224252B1 (en) | 2014-11-24 | 2019-01-09 | Medifron Dbt Inc. | Substituted oxazole- and thiazole-based carboxamide and urea derivatives as vanilloid receptor ligands ii |
CN106349451B (zh) | 2015-07-14 | 2020-11-13 | 罗门哈斯公司 | 用于制备疏水改性环氧烷氨基甲酸酯聚合物的方法 |
US10464911B2 (en) | 2015-07-27 | 2019-11-05 | Chong Kun Dang Pharmaceutical Corp. | 1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
MY190301A (en) | 2015-07-27 | 2022-04-13 | Chong Kun Dang Pharmaceutical Corp | 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same |
US10538498B2 (en) * | 2015-07-27 | 2020-01-21 | Chong Kun Dang Pharmaceutical Corp. | 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
DK3331864T3 (da) * | 2015-08-04 | 2021-12-13 | Chong Kun Dang Pharmaceutical Corp | 1,3,4-Oxadiazolderivat-forbindelser som histon-deacetylase-6-hæmmer, og den farmaceutiske sammensætning omfattende disse |
KR101839137B1 (ko) | 2015-10-12 | 2018-03-26 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 옥사다이아졸 아민 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
-
2016
- 2016-10-11 KR KR1020160131245A patent/KR101839137B1/ko active IP Right Grant
- 2016-10-11 MY MYPI2018701042A patent/MY196174A/en unknown
- 2016-10-11 HU HUE16855690A patent/HUE061967T2/hu unknown
- 2016-10-11 NZ NZ740809A patent/NZ740809A/en unknown
- 2016-10-11 WO PCT/KR2016/011355 patent/WO2017065473A1/en active Application Filing
- 2016-10-11 CA CA3001666A patent/CA3001666C/en active Active
- 2016-10-11 ES ES16855690T patent/ES2940413T3/es active Active
- 2016-10-11 MX MX2018004447A patent/MX2018004447A/es unknown
- 2016-10-11 CN CN201680072029.8A patent/CN108699048B/zh active Active
- 2016-10-11 PT PT168556900T patent/PT3362445T/pt unknown
- 2016-10-11 FI FIEP16855690.0T patent/FI3362445T3/fi active
- 2016-10-11 AU AU2016338118A patent/AU2016338118B2/en active Active
- 2016-10-11 US US15/763,972 patent/US10494355B2/en active Active
- 2016-10-11 PL PL16855690.0T patent/PL3362445T3/pl unknown
- 2016-10-11 DK DK16855690.0T patent/DK3362445T3/da active
- 2016-10-11 JP JP2018518487A patent/JP6697074B2/ja active Active
- 2016-10-11 HR HRP20230201TT patent/HRP20230201T1/hr unknown
- 2016-10-11 RU RU2018117502A patent/RU2695133C1/ru active
- 2016-10-11 EP EP16855690.0A patent/EP3362445B1/en active Active
- 2016-10-12 TW TW105132939A patent/TWI694073B/zh active
-
2018
- 2018-04-10 PH PH12018500773A patent/PH12018500773A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20170043091A (ko) | 2017-04-20 |
CN108699048A (zh) | 2018-10-23 |
DK3362445T3 (da) | 2023-02-27 |
EP3362445A4 (en) | 2019-05-22 |
CN108699048B (zh) | 2021-12-28 |
JP6697074B2 (ja) | 2020-05-20 |
EP3362445A1 (en) | 2018-08-22 |
FI3362445T3 (fi) | 2023-03-21 |
PT3362445T (pt) | 2023-03-20 |
MX2018004447A (es) | 2018-08-01 |
KR101839137B1 (ko) | 2018-03-26 |
AU2016338118A1 (en) | 2018-04-12 |
AU2016338118B2 (en) | 2019-03-14 |
US10494355B2 (en) | 2019-12-03 |
ES2940413T3 (es) | 2023-05-08 |
MY196174A (en) | 2023-03-20 |
EP3362445B1 (en) | 2023-01-25 |
US20180273495A1 (en) | 2018-09-27 |
PH12018500773B1 (en) | 2018-10-29 |
CA3001666C (en) | 2021-03-30 |
TWI694073B (zh) | 2020-05-21 |
JP2018530571A (ja) | 2018-10-18 |
BR112018007289A2 (pt) | 2018-10-23 |
PH12018500773A1 (en) | 2018-10-29 |
TW201716397A (zh) | 2017-05-16 |
RU2695133C1 (ru) | 2019-07-22 |
NZ740809A (en) | 2019-04-26 |
CA3001666A1 (en) | 2017-04-20 |
HUE061967T2 (hu) | 2023-09-28 |
PL3362445T3 (pl) | 2023-08-07 |
WO2017065473A1 (en) | 2017-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20230201T1 (hr) | Oksadiazol aminski spojevi derivati kao inhibitor histonske deacetilaze 6 i farmaceutska kompozicija koja sadrži iste | |
JP2018530571A5 (hr) | ||
US9096571B2 (en) | Picolinamide and pyrimidine-4-carboxamide compounds, process for preparing and pharmaceutical composition comprising the same | |
CN106715415B (zh) | 3-氨基-1,5,6,7-四氢-4h-吲哚-4-酮 | |
ES2629414T3 (es) | Derivados de tiazol | |
JP2005526723A5 (hr) | ||
CA2993304C (en) | Novel compounds as ror gamma modulators | |
JP2007519754A5 (hr) | ||
CN103917528B (zh) | 嘧啶pde10抑制剂 | |
RU2011107437A (ru) | Ингибиторы кинуренин-3-моноксигеназы | |
SG181734A1 (en) | Substituted isoquinolinones and quinazolinones | |
AU2008288537B2 (en) | Novel piperazine amide derivatives | |
JP2009510097A5 (hr) | ||
HRP20110015T1 (hr) | DERIVATI IMIDAZO[1,2-a]PIRIDIN-2-KARBOKSAMIDA, NJIHOVO DOBIVANJE I NJIHOVA UPOTREBA U TERAPIJI | |
AU2003269242A1 (en) | 1,4-disubstituted piperidine derivatives and their use as 11-betahsd1 inhibitors | |
JP2016522246A5 (hr) | ||
TW200400958A (en) | Nitrogenous heterocyclic compound and pharmaceuticals thereof | |
CN1953972A (zh) | 1-氨基-酞嗪衍生物,它们的制备方法与其治疗用途 | |
NZ590951A (en) | Cyclic nucleotide phosphodiesterases PDE10 inhibitors for treating neurological disorders | |
WO2010080864A1 (en) | Piperidine-containing compounds and use thereof | |
WO1999005121A1 (es) | Derivados de acil-piperazinil-pirimidinas, su preparacion y su aplicacion como medicamentos | |
WO2006009245A1 (ja) | 含窒素縮合二環式化合物 | |
CN107108625A (zh) | 螺环衍生物 | |
CN103319470A (zh) | 基于Sant-75结构的化合物 | |
CA2769300A1 (en) | Methods and compositions for treating leukemia |